Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes

Xiao-Qian Yang, Jin Ye, Xin Li, Qian Li, Yu-Hu Song

ORCID number: Xiao-Qian Yang (0000-0001-9563-9197); Jin Ye (0000-0002-1521-1746); Xin Li (0000-0002-7381-1332); Qian Li (0000-0002-9048-762X); Yu-Hu Song (0000-0003-1952-654X).

Author contributions: Yang XQ and Song YH reviewed the literature; Song YH and Ye J established the design and conception of the paper; Li X and Li Q provided the radiological imaging data; all authors contributed to writing and revision of this review.

Supported by National Natural Science Foundation of China, No. 81570555 and No. 81770582.

Conflict-of-interest statement: The authors declare no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Received: March 17, 2019

Abstract

Hepatic sinusoidal obstruction syndrome (HSOS) can be caused by the intake of pyrrolizidine alkaloids (PAs). To date, PAs-induced HSOS has not been extensively studied. In view of the difference in etiology of HSOS between the West and China, clinical profiles, imaging findings, treatment, and outcomes of HSOS associated with hematopoietic stem cell transplantation or oxaliplatin might be hardly extrapolated to PAs-induced HSOS. Reactive metabolites derived from PAs form pyrrole-protein adducts that result in toxic destruction of hepatic sinusoidal endothelial cells. PAs-induced HSOS typically manifests as painful hepatomegaly, ascites, and jaundice. Laboratory tests revealed abnormal liver function tests were observed in most of the patients with PAs-induced HSOS. In addition, contrast computed tomography and magnetic resonance imaging scan show that patients with PAs-induced HSOS have distinct imaging features, which reveal that radiological imaging provides an effective noninvasive method for the diagnosis of PAs-induced HSOS. Liver biopsy and histological examination showed that PAs-induced HSOS displayed distinct features in acute and chronic stages. Therapeutic strategies for PAs-induced HSOS include rigorous fluid management, anticoagulant therapy, glucocorticoids, transjugular intrahepatic portosystemic shunt, liver transplantation, etc. The aim of this review is to describe the pathogenesis, clinical profiles, diagnostic criteria, treatment, and outcomes of PAs-induced HSOS.

Key words: Hepatic sinusoidal obstruction syndrome; Pyrrolizidine alkaloids; Hepatic sinusoidal endothelial cells; Pyrrole-protein adducts; Diagnostic criteria; Symptomatic
Hepatic sinusoidal obstruction syndrome (HSOS), previously known as hepatic veno-occlusive disease (HVOD), is an obliterator venulitis of the terminal hepatic venules[1-5]. HSOS is typically manifested as a classical triad of weight gain, painful hepatomegaly, and jaundice. The etiologies of HSOS include cytoreductive therapy prior to hematopoietic stem cell transplantation (HSCT)[2,6-8]; oxaliplatin-containing adjuvant chemotherapy[9-15]; intake of pyrrolizidine alkaloids (PAs)-containing plants[16-21]; use of tacrolimus in liver transplantation[22]; autosomal recessive condition of veno-occlusive disease with immunodeficiency, etc. In developed countries, HSOS usually occurs in patients who have received cytoreductive therapy prior to HSCT or oxaliplatin-containing chemotherapy for colorectal carcinoma[8,23-25]. In China, the primary cause of HSOS is the ingestion of PAs-containing herbal or dietary supplements[16,20,26]. Most clinical studies have focused on HSCT-related HSOS and oxaliplatin-induced HSOS in recent decades. Given the difference in etiologies of HSOS between western countries and China, clinical profiles, imaging findings, treatment, and outcome of HSOS associated with HSCT or oxaliplatin might be hardly extrapolated to PAs-induced HSOS.

The purposes of this review were: (1) To elucidate the pathogenesis of PAs-induced HSOS; (2) To describe clinical manifestations; (3) To describe imaging features; (4) To define the criteria for diagnosis; and (5) To evaluate treatment and outcome.  

PATHOGENESIS

HSOS is characterized by toxic injury to small hepatic vessels, particularly the sinusoidal endothelium in zone 3 of the liver acinus[27]. Damaged sinusoids lead to sloughing and downstream occlusion of terminal hepatic venules[27]. A core pathogenic event of HSOS is toxic destruction of hepatic sinusoidal endothelial cells (HSECs)[1]. Injured HSECs and central venous endothelial cells can be replaced by progenitor cells derived from bone marrow, and toxicity of the drugs and the plants to bone marrow progenitors impairs the replacement of the injured endothelial cells[28,29]. All these indicated toxic injury to sinusoidal/central venous endothelial cells and bone marrow progenitors contributes to the pathogenesis of HSOS.

PAs-containing plants are widely distributed in the world. More than 300 PAs have been identified in over 6000 plants[5]. Although the precise mechanism of PAs-induced HSOS remains unknown, it is well accepted that the initial event in PAs-induced HSOS is toxic destruction of HSECs in zone 3 of the liver acinus by toxic metabolites of PAs[16,17]. Firstly, water-soluble PAs salts are readily absorbed from the gastrointestinal tract and then transported to the liver through the portal venous system when individuals ingest herbal remedies or herbal teas containing PAs. Then, in liver, PAs are metabolized through cytochrome-P450-mediated activation to produce dehydropyrrolizidine alkaloids (DHPAs) and dehydroretronecine (DHR). DHPAs...
and DHR further interact with glutathione (GSH) or proteins to generate pyrrole-glutathione conjugates[30] or pyrrole-protein adducts (PPAs)[31], respectively. PPAs are believed to be the primary cause of PAs-induced HSOS[32,33]. GSH conjugation of DHPAs and DHR is a main detoxification mechanism in metabolism-mediated PAs intoxication[18,34]. HSECs have a low basal GSH level, thus HSEC is susceptible to the reactive metabolites with severe GSH depletion and PPAs formation[34]. PPAs covalently bind to the F-actin cytoskeleton of the HSECs, which results in depolymerization of F-actin. Depolymerization of F-actin triggers the release of matrix metalloproteinase (MMP)-9. The combination of F-actin depolymerization, which allows HSECs to round up, and degradation of the subcellular extracellular matrix by MMP-9, which loosens HSECs tethering to the space of Disse, creates gaps within and between HSECs[33]. Then, erythrocytes, leukocytes, and cellular debris penetrate the gaps in the endothelium into the space of Disse, and the sinusoidal lining consisting of HSECs, Kupffer cells, and hepatic stellate cells is dissected. Emboli of dead sinusoidal lining cells obstruct the sinusoidal flow. With progressively narrowing venous lumen and reduced sinusoidal venous outflow, post-sinusoidal portal hypertension occurred[35]. In addition, the occlusion of the small centrilobular veins leads to hepatic congestion and subsequent hemorrhagic parenchymal necrosis. This pathophysiological process gives rise to the presence of the clinical syndrome of HSOS, including weight gain, ascites, painful hepatomegaly, and jaundice[31] (Figure 1).

CLINICAL MANIFESTATION AND LABORATORY TESTS

The clinical presentation of HSOS includes jaundice, right upper quadrant pain, tender hepatomegaly, ascites, and weight gain. In western countries, HSOS occurs most commonly in cytoreductive therapy prior to HSCT or oxaliplatin-containing chemotherapy. For HSCT-related HSOS, the patients present with a wide spectrum of severity. Severe HSOS is typically associated with multiorgan failure. For oxaliplatin-induced HSOS, clinical manifestations of the patients appear to be mild or absent[9,13,36]. This indicates that clinical presentation of HSOS correlates with the etiology of HSOS. To determine the clinical presentation of the patients with PAs-induced HSOS, clinical profiles of patients with PAs-induced HSOS have been analyzed. The clinical presentation of the patients is summarized in Table 1. The most common clinical features were ascites (98%-100%), hepatomegaly (65.1%-92%), jaundice (39.8%-57.8%), and abdominal distention (98.3%-99.1%); whereas, a small proportion of PAs-induced HSOS patients had weight gain (16%-18%), edema (37.3%-39.5%), and right upper quadrant pain (19.7%-36.4%). In addition, splenomegaly (27%-34%) and gastroesophageal varices (18.3%-36.8%) were observed in a small proportion of patients with PAs-induced HSOS[17,26,37-39].

In addition, laboratory tests have been analyzed in patients with PAs-induced HSOS. The results of laboratory tests are summarized in Table 1. Routine blood tests showed that levels of erythrocytes, leukocytes, and platelets were within the normal range in most patients with PAs-induced HSOS. Abnormal liver function was observed in most PAs-induced HSOS patients. Elevation of serum bilirubin, alanine aminotransferase, aspartate aminotransferase, and y-glutamyl transpeptidase was observed in patients with PAs-induced HSOS; moreover, albumin level was abnormal (Table 1). Ascites is the most common clinical presentation of PAs-induced HSOS, and laboratory investigation showed that patients had a serum ascites albumin gradient > 11 g/L, which indicated portal hypertensive ascites[30]. A wide spectrum of disease severity was observed in patients with PAs-induced HSOS. Mild HSOS is considered when it meets diagnostic criteria and has a self-limiting course. Patients with severe HSOS developed multiorgan failure and had a high risk of mortality.

IMAGING FEATURES

The use of imaging techniques to evaluate liver lesions has been confirmed in clinical practice. Ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI) have been widely used in diagnosing liver diseases. Recently, several researchers have investigated the imaging characteristics of PAs-induced HSOS and determined the diagnostic value of radiological imaging. Imaging techniques provide valuable imaging signs as well as an effective method for diagnosing PAs-induced HSOS.

Liver ultrasonography is a cost-effective method in the diagnosis of liver diseases. A recent study demonstrated that ultrasonography is useful for diagnosis of PAs-induced HSOS. Doppler ultrasound examination of patients with PAs-induced HSOS
includes hepatomegaly, decreased portal vein flow velocity, and hepatic vein stenosis\(^{(17)}\). In addition, typical ultrasonic features include heterogeneous enhancement of the arterial phase, slow portal vein filling, and an extended transit time between the hepatic artery and vein\(^{(16,40)}\).

Several studies have described radiological features of PAs-induced HSOS. Early studies described the imaging features of PAs-induced HSOS based on small samples. They found that ascites, patchy liver enhancement, narrowing of the right hepatic vein, hepatomegaly, and gallbladder wall thickening are common features of CT (Figure 2)\(^{(19,41)}\). Recently, our group\(^{(39)}\) and Zhuge et al\(^{(17)}\) confirmed the above findings in large sample sizes. Besides this, heterogeneous hypoattenuation, pleural effusion, obscure or invisible hepatic veins, and stenosis of the hepatic segmental inferior vena cava were observed in most patients (Figure 2). Splenomegaly and portosystemic collateral circulation were observed in a small proportion of patients with PAs-induced HSOS\(^{(16,17,39)}\). Importantly, we found that patchy liver enhancement and heterogeneous hypoattenuation were valuable signs of PAs-induced HSOS\(^{(39)}\). Quantitative analysis of CT images revealed that the ratio of hepatic lesion volume to liver volume in patients with PAs-induced HSOS is associated with clinical course and outcome\(^{(42)}\).

MRI is a good choice of imaging technique because it yields different information and does not have the hazards of X-rays compared with CT. Recent studies demonstrated MRI is useful in detecting oxaliplatin-induced HSOS in patients with metastatic colon cancer\(^{(11,15,36,43)}\). Our previous work demonstrated that the common signs of PAs-induced HSOS include ascites, heterogeneous hypointensity, narrowing of the inferior vena cava, perportal edema, gallbladder wall thickening, hepatomegaly, abnormal hepatic vein (narrowing or invisibility of right hepatic vein), and pleural effusion (Figure 3). We have also found inhomogeneous enhancement around the hepatic veins (“claw” type enhancement) in the portal venous phase that results from differential blood perfusion in the peripheral and central region of the liver parenchyma as well as hypointensity in susceptibility-weighted imaging (SWI) and T2*-weighted imaging (T2*WI)\(^{(44)}\) (Figure 3). Hemosiderin derived from extravasated erythrocytes in the space of Disse is detected by T2*WI and SWI, which results in the imaging sign of hypointensity. We have also investigated the imaging features of PAs-induced HSOS on gadoxetic acid-enhanced MRI\(^{(45)}\). Heterogeneous hypointensity of liver parenchyma in hepatobiliary phase (HBP) is an imaging sign of PAs-induced HSOS (Figure 3). The severity of heterogeneous hypointensity scored by volume fraction in HBP of gadoxetic acid-enhanced MRI is positively correlated with prothrombin time and international normalized ratio, and the severity of
Table 1  Demographic information, clinical manifestation, and laboratory tests of pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome

| Reference | Wang et al[37] | Zhuge et al[17] | Song et al[38] | Wang et al[26] |
|-----------|----------------|----------------|---------------|---------------|
| Number    | n = 117        | n = 108        | n = 116       | n = 84        |
| Sex (male/female) | 78/39          | 66/42          | 78/38         | 45/39         |
| Age (yr)  | 63 (52.5-69)²  | 61 (55-69)²    | 56.92 ± 12.39² | 52.97 ± 15.28² |
| Clinical manifestation | | | | |
| Ascites   | 99.1% (116/117) | 98% (50/51) | 100% (79/79) | 100% (83/83) |
| Hepatomegaly | 70% (82/117)  | 92% (47/51) | 75.95% (79/117) | 65.1% (54/83) |
| Abdominal distention | 98.3% (115/117) | 99% (107/108) | 98.3% (115/115) | 98% (115/115) |
| Jaundice  | 39.8% (43/108) | 39.5% (43/109) | 37.3% (31/83) | 37.3% (31/83) |
| Right upper quadrant pain | 19.7% (23/117) | 21.1% (11/117) | 36.4% (40/110) | 36.4% (40/110) |
| Edema     | 39.3% (46/117) | 39.5% (46/109) | 39.8% (31/83) | 39.8% (31/83) |
| Splenomegaly | 34.2% (40/117) | 27% (14/51) | 25.35% (18/71)[39] | 25.35% (18/71)[39] |
| Gastroesophageal varices | | | 18.31%(13/71)[39] | 18.31%(13/71)[39] |

| Laboratory tests | Variable | median (25th-75th percentiles) | median (25th-75th percentiles) | mean ± SD | mean ± SD |
|------------------|----------|--------------------------------|---------------------------------|-----------|-----------|
| ALT (U/L)        | 49 (25.0-152.5) | 52.6 (26.8-125) | 134.50 ± 154.89 | 216.83 ± 235.78 |
| AST (U/L)        | 75 (39.0-158.5) | 69.6 (42.4-115) | 146.31 ± 156.30 | 221.15 ± 221.70 |
| ALP (U/L)        | 122 (86.8-191.3) | 130 (105-178) | 170 ± 106.89 | 183.48 ± 59.96 |
| γ-GT (U/L)       | 100.7 (61.8-164.8) | 120 (72.4-170) | 160.52 ± 114.56 | 155.70 ± 99.45 |
| TB (μmol/L)      | 33.3 (19.7-47.0) | 39.7 (28.3-62.4) | 65.07 ± 78.83 | 52.96 ± 45.95 |
| ALB (g/L)        | 30.6 (27.7-33.6) | 32.1 (29.8-34.7) | 30.71 ± 5.30 | 32.02 ± 5.30 |
| PT (sec)         | 14.8 (12.7-17.0) | 15.1 (14.2-16.7) | 17.43 ± 2.64 | 18.08 ± 4.12 |
| WBC (10⁹/L)      | 6.1 (5.0-8.7) | 6.1 (4.8-7.3) | 6.90 ± 2.81 | 6.90 ± 2.81 |
| RBC (10¹²/L)     | 4.4 (3.9-4.9) | 5 ± 4.33 | 114.06 ± 63.48 | 114.06 ± 63.48 |
| PLT (10⁹/L)      | 113 (78-153) | 95 (74-134) | 114.06 ± 63.48 | 114.06 ± 63.48 |

1Continuous variables were expressed as medians (25th-75th percentiles);
2Continuous data were expressed as mean ± standard deviations. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; γ-GT: γ-Glutamyl transpeptidase; TB: Total bilirubin; ALB: Albumin; PT: Prothrombin time; WBC: White blood cell; RBC: Red blood cell; PLT: Platelet.

hypointensity in HBP is a mortality risk factor. In summary, these studies have demonstrated that heterogeneous hypoattenuation/hypointensity and irregular enhancement are valuable imaging features of CT and MRI.

PATHOLOGY

Liver biopsy and histological examination are gold standards for diagnosis of HSOS. PAs-induced HSOS exhibits acute and subacute/chronic features. In the early stage, the first recognizable histological change is widening of the subendothelial zone between the basement membrane and the adventitia of central veins and sublobular veins[46,47]. In acute disease, swelling, damage, and shedding of HSECs are observed in acinar zone 3 (Figure 4). Significant dilation and congestion of hepatic sinusoids with centrilobular hepatocellular necrosis, dissection of erythrocytes into the space of Disse, thickening of the walls of small intrahepatic veins with narrowing and occlusion of the lumen are frequently observed[16,38]. In the later stage, deposition of extracellular matrix in subendothelial spaces and sinusoids and extensive collagenization of sinusoids and venules were characteristic histological features[38]. In addition, our studies also found complete loss of pericentral hepatocytes as well as sinusoidal dilatation in subacute or chronic stages (Figure 4)[38]. However, percutaneous liver biopsy is difficult to perform in patients with PAs-induced HSOS due to extensive ascites, coagulation disorders, and thrombocytopenia. Furthermore, the uneven distribution of HSOS decreases histopathological credibility. Transjugular liver biopsies have been performed in PAs-induced HSOS patients with extensive ascites, coagulation disorders, and thrombocytopenia. More importantly, transjugular
liver biopsy with hepatic venous pressure gradient (HVPG) provides valuable information. HVPG > 10 mmHg has > 90% specificity and > 85% positive predictive value for the diagnosis of HSOS following HSCT. In a retrospective study, seven patients with PAs-induced HSOS underwent HVPG measurement, and they all had a significant increase in HVPG (mean value 23.50 ± 3.02 mmHg). However, this technique has not been widely used in many hospitals because it requires a dedicated setting and is expensive.

CRITERIA FOR DIAGNOSIS OF PAs-INDUCED HSOS

In clinical practice, the combination of history, clinical manifestation, laboratory data, imaging, biomarkers, and pathological findings has established diagnosis of diseases. Diagnosis of HSOS relies on history, clinical symptoms, laboratory examination, imaging, biomarkers, and liver histopathology. To date, most of the studies on diagnostic criteria of HSOS have focused on HSCT-related HSOS. The diagnosis of HSCT-related HSOS is largely based on history and the classical triad of weight gain, painful hepatomegaly, and jaundice. Symptoms of HSCT-related HSOS occur within 10 d after HSCT. Established clinical criteria, including modified Seattle and Baltimore criteria, require that patients must be within 21 d after HSCT to establish the diagnosis (Table 2). Cytoreductive therapy prior to HSCT is essential for diagnosis of HSOS. However, late onset HSOS/HVOD beyond day 21 has been reported. The researchers thus recommended including late onset HSOS/HVOD (beyond day 21) in HSCT-related HSOS.

Since clinical manifestations of the PAs-induced HSOS and HSCT-related HSOS are similar, some of the diagnostic criteria for PAs-induced HSOS have been developed according to those for HSCT-related HSOS (Table 2). History of PAs exposure is essential to establish the diagnosis. However, PAs exposure is always obscure, due to variability of the plant components, storage conditions for the plant products, mislabeling or misidentification of the plant, and outright contamination. Fortunately, a serum biomarker derived from toxic PAs metabolites has been identified in patients with PAs-induced HSOS. PAs are used as biomarkers of toxic PAs exposure. PPAs measured by ultra-performance liquid chromatography–tandem mass spectrometry are highly sensitive and specific for diagnosis of PAs-induced HSOS. Thus, the measurement of PPAs should be used together with the conventional HSOS clinical criteria for definitive diagnosis of PAs-induced HSOS. Given this, a history of PAs exposure, biomarkers, and clinical symptoms provide important evidence for the diagnosis of PAs-induced HSOS. Thus, the diagnostic criteria proposed by Gao et al were as follows: (1) Meeting the criteria for drug-induced liver injury, Roussel Uclaf Causality Assessment Method score > 3; (2) Meeting the modified Seattle criteria for HSOS; and (3) A history of PAs exposure and detection of PPAs. These criteria (Table 2) have been used in some studies. However, blood PPA concentrations decrease after 40 d exposure to PAs. Moreover, blood PPA concentration is related to the severity of HSOS, and PAs metabolites bind with multiple serum proteins that affect blood PPA concentration. All these confined the diagnostic value of PPA determination. More importantly, this assay is not performed in most hospitals.

Recently, some studies have described the imaging signs of PAs-induced HSOS and demonstrated the diagnostic value of the imaging techniques. Histopathological findings provide confirmative evidence of PAs-induced HSOS. Thus, imaging techniques and liver biopsy were incorporated into the Nanjing Criteria (proposed by the Chinese Society of Gastroenterology Committee of Hepatobiliary
Figure 3  A 53-year-old man with pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome (same patient) received gadoxetic acid-enhanced magnetic resonance imaging scan. A: T1-weighted imaging. Ascites (white star), heterogeneous hypointensity (white arrow) were shown; B and C: T2-weighted imaging. Imaging findings included ascites (black star, B), gallbladder wall thickening (white arrow, B), periporal edema (arrowhead, C), heterogeneous hypointensity (white arrow, C); D and E: T2*WI (D) and SWI (E). Heterogeneous hypointensity (white arrow) was observed, and distribution of hypointensity in SWI and T2*WI was similar; F: Image of portal venous phase. Patchy liver enhancement, “claw-shaped” enhancement surrounding hepatic veins (white arrow), stenosis of right hepatic vein (arrowhead) and inferior vena cava (black arrow); G: Image of hepatobiliary phase. Heterogeneous hypointensity (white arrow) was shown. SWI: Susceptibility-weighted imaging; T2*WI: T2*-weighted imaging.

Disease). However, prospective data on performance of Nanjing Criteria have not been provided until now, and further studies should be performed to evaluate their diagnostic performance in large sample sizes. Another important issue is the classification of staging and severity. Unfortunately, the natural course and severity of PAs-induced HSOS are still unknown, and relevant data are not available.

TREATMENT

Current management of PAs-induced HSOS is a challenge for hepatologists. Unfortunately, no definitive treatment for PAs intoxication is available. The therapeutic strategies for PAs-induced HSOS consists of termination of PAs exposure, symptomatic treatment, anticoagulant therapy, transjugular intrahepatic portosystemic shunt (TIPS), liver transplantation, etc. Importantly, different strategies should be performed in patients with PAs-induced HSOS according to disease severity and stage. In mild cases as spontaneous recovery occurs, symptomatic treatment is needed\[52\]. In severe cases, symptomatic treatment, anticoagulant therapy, TIPS, or liver transplantation should be performed.

Symptomatic treatment is important for PAs-induced HSOS and includes discontinued exposure to PAs, liver protection, and management of ascites. The latter consists of restriction of water and sodium supply, use of diuretics, albumin infusion, serial paracentesis, and TIPS. Oral furosemide and spirolactone are preferentially used for diuretic therapy. Albumin infusion is beneficial in patients with hypoalbuminemia. Serial paracentesis is recommended in patients who have poor response to diuretics. TIPS may be considered to control refractory ascites. Hemodialysis and mechanical airway protection may be required in HSOS patients with multiorgan failure.

Recent studies have demonstrated the beneficial effect of anticoagulant therapy in prevention of HSCT-related HSOS; however, a systematic review and meta-analysis showed negative results\[53\]. Recently, some studies have been performed to determine the effect of anticoagulant therapy on PAs-induced HSOS. In a retrospective study reported by Nanjing Drum Tower hospital, anticoagulant therapy (low molecular weight heparin combined with warfarin) significantly improved response rate of patients with PAs-induced HSOS compared with the non-anticoagulant group (60% vs 27%)\[53\]. A retrospective study from the first Affiliated Hospital of Zhengzhou University confirmed these results\[53\]. In addition, some of the studies demonstrated the effectiveness of anticoagulant therapy in Chinese journals\[54-56\]. Thus, Chinese guidelines recommend that anticoagulant therapy should be started as soon as possible in patients with acute/subacute HSOS after ruling out contraindications. Low molecular weight heparin is the anticoagulant of choice, either combined with or followed by oral administration of warfarin. The recommended dose of low molecular weight heparin is 100 IU/kg, every 12 h, subcutaneous injection. Warfarin is the
Figure 4 Pathology of pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome. A: Acute stage (200 ×). Dilation and congestion of hepatic sinusoidal, the penetration of erythrocytes into the space of Disse; B: Subacute stage (200 ×). Complete loss of pericentral hepatocytes, sinusoidal dilatation.

preferred oral anticoagulant for long-term therapy, and the recommended international normalized ratio is 2.0-3.0, which may satisfy both the anticoagulant effect and safety. To date, prospective multicenter studies have not been performed to determine the effectiveness of anticoagulant therapy, thus large randomized control trials (RCTs) should be performed in future.

Defibrotide is the only approved drug for severe HSCT-related HSOS and HSCT-related HSOS with renal or pulmonary dysfunction in western countries[57]. Since defibrotide is not approved in China, its effectiveness remains unknown in patients with PAs-induced HSOS. Steroids have also been used in HSOS patients, and beneficial effects of early high-dose steroid therapy have been shown in severe pediatric HSCT-related HSOS[49], but adverse events such as infection should be considered. Although sporadic reports show the effectiveness of steroids in both PAs-induced HSOS patients and mouse models[59-61], the effectiveness of steroids for PAs-induced HSOS remains inconclusive and further RCTs should be performed.

TIPS may be considered when PAs-induced HSOS patients have refractory ascites or severe portal-venous hypertension. In a retrospective study, TIPS improved the prognosis of 29 patients who did not respond to symptomatic treatment plus anticoagulation[17]. While another retrospective study showed that TIPS failed to improve survival[37]. The efficacy of TIPS should be evaluated based on RCTs in the future. Liver transplantation can be considered in severe cases of PAs-induced HSOS with liver failure, and in theory, this should improve survival. Other treatments such as ursodeoxycholic acid, antithrombin III, and recombinant human thrombomodulin have been tried in HSCT-related HSOS, but the evidence in PAs-induced HSOS is lacking.

**OUTCOME**

The mortality rate of PAs-induced HSOS is reported to vary from 16% to 40%, and a common cause of death is liver failure[17,26,37,45,51]. A systematic review showed that increased total bilirubin and aspartate transaminase are indicators of poor survival in patients with PAs-induced HSOS[26]. A retrospective study of 117 cases demonstrated that hepatic encephalopathy, serum bilirubin, and albumin levels were major prognostic factors for Gynura segetum-induced HVOD[37]. In addition, Gao et al[51] demonstrated that PPA concentration was related to the severity and clinical outcome of PAs-induced HSOS.

**CONCLUSION**

The intake of PAs is one of the major etiological causes of HSOS in China. Here, we described the pathogenesis, clinical profiles, diagnostic criteria, treatment, and outcomes of patients with PAs-induced HSOS. Although progress has been made in PAs-induced HSOS, several issues remain to be resolved. A suitable animal model of PAs-induced HSOS should be established through repeated administration of PAs, which resembles the pathological status of PAs-induced HSOS in humans; the Nanjing criteria should be validated in prospective studies; disease severity grading should be developed; large-scale RCTs should be performed to determine the safety and efficacy of therapeutic strategies for PAs-induced HSOS; and prognostic factors should be accurately identified.
Table 2  Diagnostic criteria for hepatic sinusoidal obstruction syndrome

| HSCT-related HSOS | PAs-induced HSOS |
|-------------------|-------------------|
| **Classical HSOS** | **Late onset HSOS (> 21 d after HSCT)** | Criteria proposed by Gao et al[16] | **Nanjing criteria[17]** |
| **Modified Seattle criteria[1]** | **Baltimore criteria[1]** | **New EBMT criteria[1]** | **Patological evidence** |
| Presence of 2 of the following criteria within 20 d after HSCT: | | | **Presence of the following three criteria** |
| 1 Bilirubin ≥ 34.2 μmol/L; | 1 Hepatomegaly; | 1 Meeting the modified Seattle criteria | 1 Abdominal distention and/or pain in the hepatic region, hepatomegaly, and ascites; |
| 2 Hepatomegaly or right upper quadrant pain; | 2 Ascites; | 2 Meeting the criteria for DILI | 2 Increased serum total bilirubin or other abnormal liver function; |
| 3 Weight gain > 2% | 3 Weight gain > 5% | 3 A history of taking PAs-containing herbs; detection of PAs | 3 Typical contrast-enhanced CT or MRI findings |
| | AND hemodynamical or/and ultrasound evidence of HSOS | | |

HSCT: Hematopoietic stem cell transplantation; HSOS: Hepatic sinusoidal obstruction syndrome; HVOD: Hepatic veno-occlusive disease; PAs: Pyrrolizidine alkaloids; DILI: Drug-induced liver injury; PPAs: Pyrrole-protein adducts; CT: Computed tomography; MRI: Magnetic resonance imaging.

REFERENCES

1. Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol 2014; 4: 332-346 [PMID: 25755580 DOI: 10.1016/j.jceh.2014.10.002]
2. Plessier A, Rastou PE, Valla DC. Management of hepatic vascular diseases. J Hepatol 2012; 56 Suppl 1: S25-S38 [PMID: 22300463 DOI: 10.1016/S0168-8278(12)60004-X]
3. DeLeve LD, Valla DC, Garcia-Tsao G; American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009; 49: 1729-1764 [PMID: 19399912 DOI: 10.1002/hep.22772]
4. Bayraktar UD, Seren S, Bayraktar Y. Hepatic venous outflow obstruction: Three similar syndromes. World J Gastroenterol 2007; 13: 1912-1927 [PMID: 17461490 DOI: 10.3748/wjg.v13.i13.1912]
5. Chojkier M. Hepatic sinusoidal-obstruction syndrome: Toxicity of pyrrolizidine alkaloids. J Hepatol 2003; 39: 437-446 [PMID: 12927933 DOI: 10.1016/S0168-8278(03)00231-9]
6. Mohsy M, Malard F, Abeassis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Bazabache A, Blaise D, Ciceri F, Corbicougli S, Daile JH, Dignan F, Fukuda T, Huyhn A, Masszi T, Michallet M, Nagler A, N’Gonbaa-Mia M, Okamoto S, Pagliuca A, Peters C, Petersen FB, Richardson PG, Rauu T, Savani BN, Wallhult E, Yakoub-Agha I, Duarte RF, Carreras E. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/hepatic-occlusive disease in adult patients: A new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2016; 51: 906-912 [PMID: 27183098 DOI: 10.1038/bmt.2016.130]
7. Yakshejirin K, Atsuna Y, Doki N, Yokota A, Kamamori H, Miyamoto T, Owabata C, Miyamura A, Nawa Y, Kurokawa M, Mizuno I, Mori T, Onizuka M, Taguchi J, Ichiho T, Hane H, Morishima Y, Kato K, Suzuki R, Fukuda T. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Bone Marrow Transplant 2016; 51: 403-409 [PMID: 26595062 DOI: 10.1038/bmt.2015.283]
8. Dignan FL, Wynn RF, Hadzie N, Karani J, Quaglia A, Pagliuca A, Veys P, Potter MN; Haematology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. BCSH/BBSMT guideline: Diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 2013; 163: 444-457 [PMID: 24102514 DOI: 10.1111/bjh.12558]
9. Liu F, Cao X, Ye J, Pan X, Kan X, Song Y. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome in a patient with gastric cancer: A case report. Mol Clin Oncol 2018; 8: 453-456 [PMID: 29468059 DOI: 10.3892/mco.2017.1540]
10. Choi JH, Won YW, Kim HS, Oh YH, Lim S, Kim HJ. Oxaliplatin-induced sinusoidal obstruction syndrome mimicking metastatic colon cancer in the liver. Oncol Lett 2016; 11: 2861-2864 [PMID: 27073565 DOI: 10.3892/ol.2016.4286]
11. Han NY, Park BJ, Sung DJ, Kim MJ, Cho SB, Lee CH, Jang YJ, Kim SY, Kim DS, Um SH, Won NH, Yang KS. Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy:
Gadoxetic acid–enhanced and diffusion-weighted MR imaging with clinical-pathologic correlation. 

Radiology. 2014; 271: 416-425 [PMID: 24475862 DOI: 10.1148/radiol.131318110]

12 Imai K, Enri Y, Iyama KI, Beppu T, Ogata Y, Kakeji Y, Samura H, Oki E, Akaogi Y, Maehara Y, Baba H, Kusuyama Study Group of Clinical Cancer (KSCC) ancillary study. Spleen volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Eur J Surg Oncol 2014; 40: 559-566 [PMID: 24388740DOI: 10.1016/j.ejso.2013.12.009]

13 Han NY, Park BJ, Kim MJ, Sung DJ, Cho SB. Hepatic Parenchymal Heterogeneity on Contrast-enhanced CT Scans Following Oxaliplatin-based Chemotherapy: Natural History and Association with Clinical Evidence of Sinusoidal Obstruction Syndrome. Radiology 2015; 276: 766-774 [PMID: 25524271 DOI: 10.1148/radiol.2015141749]

14 Agostini J, Benoist S, Seman M, Julic C, Imbeaud S, Letourneur F, Cagnar N, Rouger P, Brouquet A, Zucman-Rossi J, Laurent-Puig P. Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. J Hepatol 2012; 56: 869-876 [PMID: 22206673DOI: 10.1016/j.jhep.2011.06.016]

15 Ward J, Guthrie JA, Sheridan MB, Sorensen J, Wilson D, Wyatt JI, Treanor D, Robinson PJ. Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol 2008; 26: 4304-4310 [PMID: 18779617DOI: 10.1200/JCO.2008.16.1893]

16 Zhang Y, Liu Y, Xie W, Zou X, Xu J, Wang J. Chinese Society of Gastroenterology Committee of Hepatobiliary Disease. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatol 2019; 34: 634-642 [PMID: 30669184DOI: 10.1111/jgh.14612]

17 Zhuge YZ, Wang Y, Zhang F, Zha CK, Zhang W, Zhang M, He Q, Yang J, He J, Chen J, Zou XP. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease. Liver Int 2018; 38: 1867-1874 [PMID: 29297975DOI: 10.1111/liv.13684]

18 Yang M, Ruan J, Gao H, Li N, Ma J, Xue J, Ye Y, Fu PP, Wang J, Lin G. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans. Arch Toxicol 2017; 91: 3913-3925 [PMID: 28620673DOI: 10.1007/s00204-017-1315-y]

19 Zhou H, Wang YX, Lou HY, Xu XJ, Zhang MM. Hepatic sinusoidal obstruction syndrome caused by herbal medicine: CT and MRI features. Korean J Radiol 2014; 15: 218-225 [PMID: 24643319DOI: 10.3348/kjr.2014.15.2.218]

20 Wang JY, Gao H. Tusanqi and hepatic sinusoidal obstruction syndrome. J Dig Dis 2014; 15: 105-107 [PMID: 24528632DOI: 10.1111/1757-2225.12012]

21 Lin G, Wang YJ, Li N, Li M, Gao H, Ji Y, Zhang F, Wang H, Zhou Y, Ye Y, Xu HX, Zhang J. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol 2011; 54: 666-673 [PMID: 21146894DOI: 10.1016/j.jhep.2010.07.031]

22 Shen T, Feng XW, Geng L, Zheng SS. Reversible sinusoidal obstruction syndrome associated with tacrolimus following liver transplantation. World J Gastroenterol 2015; 21: 6422-6426 [PMID: 26034382DOI: 10.3748/wjg.v21.i20.6422]

23 MOTHY M, Malard F, Abeccasis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dallocchi JH, Duarte RF, Fukuda T, Huyah N, Massiti T, Michallet M, Nagler A, NiChonghaile M, Pagnucco T, Peters C, Petersen FB, Richardson PG, Ruutu T, Savani BN, Wallhult E, Yakoub-Agha I, Carreras E. Sinusoidal obstruction syndrome/veno-occlusive disease: Current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2015; 50: 781-789 [PMID: 25796862DOI: 10.1038/bmt.2015.52]

24 Morine Y, Shimada M, Usunomiya T. Evaluation and management of hepatic injury induced by oxaliplatin-based chemotherapy in patients with hepatic resection for colorectal liver metastasis. Hepatol Res 2014; 44: 59-69 [PMID: 23551330DOI: 10.1111/hepr.12107]

25 Robinson SM, Mann J, Vasiliki A, Mathers J, Burt AD, Oakley F, White SA, Mann DA. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol 2013; 59: 318-326 [PMID: 23624001DOI: 10.1016/j.jhep.2013.04.014]

26 Wang X, Qi X, Guo X. Tusanqi-Related Sinusoidal Obstruction Syndrome in China: A Systematic Review of the Literatures. Medicine (Baltimore) 2015; 94: e942 [PMID: 26661322DOI: 10.1097/MD.0000000000000942]

27 Valla DC, Cazals-Hatem D. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol 2016; 40: 378-385 [PMID: 27033846DOI: 10.1016/j.clinre.2016.01.006]

28 Harb R, Xie G, Lutzko C, Gao Y, Wang X, Hill CK, Kanel GC, DeLeve LD. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury. Gastroenterology 2009; 137: 704-712 [PMID: 19447108DOI: 10.1053/j.gastro.2009.05.009]

29 Wang L, Wang X, Wang L, Chiu JD, van de Ven G, Gaarde WA, Deleve LD. Hepatic vascular endothelial growth factor regulates recruitment of rat liver sinusoidal endothelial cell progenitor cells. Gastroenterology 2012; 143: 1555-1563.e2 [PMID: 22962870DOI: 10.1053/j.gastro.2012.08.008]

30 Lin G, Cui YY, Hawes EM. Characterization of rat liver microsomal metabolites of clireotide, an hepatotoxic oxalato-type pyrrolizidine alkaloid. Drug Metab Dispos 2000; 28: 1475-1483 [PMID: 11095586DOI: 10.1128/dmd.10.6.1475-1483.2000]

31 Mattocks AR. Toxicity of pyrrolizidine alkaloids. Nature 1968; 217: 723-728 [PMID: 5641123DOI: 10.1038/217723a]

32 Mattocks AR. Bird I. Alkylation by dehydroreticine, a cytotoxic metabolite of some pyrrolizidine alkaloids: An in vitro test. Toxicol Lett 1983; 16: 1-8 [PMID: 6836605DOI: 10.1016/0378-4274(83)90002-4]

33 Yanc CC, Huxtable RJ. Quantitation of the hepatic release of metabolites of the pyrrolizidine alkaloid, monocrotaline. Toxicol Appl Pharmacol 1994; 127: 58-63 [PMID: 8048054DOI: 10.1016/0041-008X(94)90139-7]

34 Yang M, Ruan J, Fu PP, Lin G. Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: Firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity. Chem Biol Interact 2016; 243: 119-126 [PMID: 26365561DOI: 10.1016/j.cbi.2015.09.011]

35 Nakamura K, Hatanou E, Narita M, Miyagawa-Hayashino A, Koyama Y, Nagata H, Iwaisako K, Taura K, Uemoto S. Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9. J Hepatol 2012; 57: 1037-1043 [PMID: 22796153DOI: 10.1016/j.jhep.2012.07.004]

36 Shin NY, Kim MJ, In JS, Park MS, Chung YE, Choi JY, Kim KW, Park YN. Accuracy of gadoxetic
acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. *Eur Radiol* 2012; 22: 864-871 [PMID: 22108776 DOI: 10.1007/s00330-011-2335-x]

37 Wang Y, Guo D, Li Y, Xu F. Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: A retrospective study. *BMC Gastroenterol* 2018; 18: 156 [PMID: 30367628 DOI: 10.1186/s12876-018-0879-7]

38 Song Y, Liu F, R X, Guo H, Xu D. Pyrrolizidine alkaloid-induced hepatic sinusoidal obstructive syndrome clinical characteristics, imaging signs and pathological findings. *J Hepatol* 2018; 68: 5396 [DOI: 10.1016/j.jhep.2018.05.005]

39 Kan X, Ye J, Rong X, Lu Z, Li X, Wang Y, Yang L, Xu K, Song Y, Hou X. Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome. *Sci Rep* 2016; 6: 37998 [PMID: 27897243 DOI: 10.1038/srep37998]

40 Jiang TA, Weng HF, Ao JY, Chen F, Zhao QY, Huang M, Chen Y. Diagnostic Value of Ultrasonography in Diagnosing Hepatic Sinusoidal Obstructive Syndrome. *Zhongguo Chaosheng Yixue Zazhi* 2008; 24: 951-955

41 Wu XW, Wang WQ, Liu B, Xu JM, Yu YQ, Zhang S, Shen Y. Hepatic veno-occlusive disease after taking Gynura Rizome: The value of multidetector computed tomography in diagnosing the disease and evaluating the clinical therapeutic effect. *Hepatol Res* 2012; 42: 304-309 [PMID: 22136416 DOI: 10.1111/j.1872-034X.2011.00918.x]

42 Wang C, Wu X, Xie W, Ren X, Zhang W, Xu J. Quantitative Analysis of CT Images in Patients with Pyrrolizidine Alkaloid-Induced Sinusoidal Obstructive Syndrome. *Sci Rep* 2019; 9: 2179 [PMID: 30773132 DOI: 10.1038/s41598-019-20669-6]

43 O'Rourke TR, Welsh FK, Tekkis PP, Lyle N, Mustajab A, John TG, Peppercom D, Rees M. Accuracy of liver-specific magnetic resonance imaging as a predictor of chemotherapy-associated hepatic cellular injury prior to liver resection. *Eur J Surg Oncol* 2009; 35: 1085-1091 [PMID: 19246171 DOI: 10.1016/j.ejsio.2009.01.015]

44 Li X, Yang X, Xu D, Li Q, Kong X, Lu B, Xu K, Li J, Song Y. Magnetic Resonance Imaging Findings in Patients With Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome. *Clin Gastroenterol Hepatol* 2017; 15: 955-957 [PMID: 28126425 DOI: 10.1016/j.cgh.2017.01.009]

45 Guo T, Li X, Yang X, Kong X, Liu H, Bai T, Xu K, Ye J, Song Y. Gadodetic Acid-Enhanced Hepatopathy-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function. *Sci Rep* 2019; 9: 1231 [PMID: 30718988 DOI: 10.1038/s41598-018-37775-1]

46 DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease). *Seminar Liver Dis* 2002; 22: 27-42 [PMID: 11928077 DOI: 10.1055/s-2002-23204]

47 Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Veno-occlusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. *Hepatology* 1994; 19: 1171-1181 [PMID: 8175139 DOI: 10.1002/hep.1840190515]

48 Shulman HM, Gooley T, Dudley MD, Kofler T, Feldman R, Dwyer D, McDonald GB. Utility of transvenous liver biopsy and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. *Transplantation* 1995; 59: 1015-1022 [PMID: 779437 DOI: 10.1097/00007096-199504150-00017]

49 Shulman HM, Hinterberger W. Hepatic veno-occlusive disease—liver toxicity syndrome after bone marrow transplantation. *Bone Marrow Transplant* 1992; 10: 197-214 [PMID: 1424275 DOI: 10.1036/s-0002-23029-P]

50 Jones RJ, Lee KS, Beschnger WH, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R. Venoocclusive disease of the liver following bone marrow transplantation. *Transplantation* 1987; 44: 778-783 [PMID: 3321587 DOI: 10.1097/00007890-198712000-00011]

51 Gao H, Ruan JQ, Chen J, Li N, Ke QO, Ye Y, Lin G, Wang JY. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. *Drug Des Devel Ther* 2015; 9: 4861-4868 [PMID: 26364783 DOI: 10.2147/DDDT.S87585]

52 Helmy A. Review article: Updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. *Aliment Pharmacol Ther* 2006; 23: 11-25 [PMID: 16393276 DOI: 10.1111/j.1365-2036.2006.02742.x]

53 Imran M, Talebjeh IM, Zirakradhe A, Rodriguez V, Khan SP. Use of prophylactic antiagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: A systematic review and meta-analysis. *Bone Marrow Transplant* 2006; 37: 677-686 [PMID: 16489362 DOI: 10.1038/sj.bmt.1705297]

54 Wang Y, Zhuo YZ, Zhang F, Zhang M, Zhang W, He QB, Zou XP. Treatment for Gynura segetum caused hepatic vein occlusive disease-a single-center retrospective study. *Zhonghua Xiu Hou Za Zhi* 2016; 36: 811-815

55 Song Y, Fan YH. Clinical features of hepatic veno-occlusive disease induced by gynura root: analysis of 102 cases. *Linchuang Gandanbing Zazhi* 2011; 27: 496-499

56 Zhu W, Chen SH, Chen WX, Li YM. Clinical analysis of 50 cases of hepatic veno-occlusive disease. *Zhongguo Xiu Hou Za Zhi* 2013; 32: 620-624

57 Richardson PG, Trislett BM, Ito VT, Chao N, Dignan FL, Maglio M, Mohyt M. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. *Expert Rev Clin Pharmacol* 2018; 11: 113-124 [PMID: 29301447 DOI: 10.1016/j.eclp.2018.12.014]

58 Myers KC, Lawrence J, Marsh RA, Davies CM, Jodell S. High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients. *Biol Blood Marrow Transplant* 2013; 19: 500-503 [PMID: 23211836 DOI: 10.1016/j.bbmt.2012.11.011]

59 Zhang YT, Li S, Zhou DH, Li J. Clinical features of sinusoidal obstruction syndrome: an analysis of 35 cases and literature review. *Linchuang Gandanbing Zazhi* 2013; 29: 936-939

60 Li ZM, Pan WS, Cai JT, Chen LR, Yao M. Successful treatment of hepatic veno-occlusive disease caused by gynura root-a case report. *Zhonghua Neike Za Zhi* 2005; 44: 144-145

61 Zhu H, Chu Y, Huo J, Chen Z, Yang L. Effect of prednisone on transforming growth factor-β1, connective tissue growth factor, nuclear factor-xBp65 and tumor necrosis factor-α expression in a murine model of hepatic sinusoidal obstruction syndrome induced by Gynura segetum. *Hepatol Res* 2011; 41: 795-803 [PMID: 21699635 DOI: 10.1111/j.1872-034X.2011.00830.x]
